This study analyzes BRCA testing patterns in U.S. breast cancer patients, highlighting barriers and disparities in access to genetic testing and precision care.

The addition of olaparib to neoadjuvant chemotherapy improved overall survival in BRCA-mutated breast cancer, despite no improvement in pathologic response. Adding the PARP inhibitor led to a 3-year ...

I spent decades hunting some of the most elusive fugitives in America. I've watched financial crimes evolve in real time from ...

Scientists have captured the most detailed structural images to date of a specific type of protein's DNA repair process, a ...

Sign up for Being Human, a newsletter that explores wellness culture, mortality and disease, and other mysteries of the body and the mind. “It’s a branding ...

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among ...

Call your local elected officials and tell them to support the BRCA, which protects developers of noncustodial technology as well as a variety of services that preserve privacy and make it easier to ...

An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan has discovered associations between pathogenic variants of the BRCA 1 and 2 genes and ...

Seven women in one family had major surgery after a widely used genetic test, taken by hundreds of thousands of people, showed a high cancer risk. But years later, the family has learned the results ...

SAN ANTONIO – Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...